LCN2 and multiple sclerosis: Different drugs were shown to decrease NGAL levels in animal models including usage of nanotherapeutics for down regulation of NGAL synthesis (29), application of the iron chelator deferoxamine in a traumatic brain injury model in rats (30) and modulation of NGAL in EAE-mice treated with natalizumab which is currently used in human multiple-sclerosis (5).